EV exclusively derived from confirmed NSCLC patients (IV+) were CD63 high and CD9 moderate) when compared to EV from false-positive patients (CD63 low and CD9 moderate) or to screening controls (II: CD63 low and CD9 low) (Fig. 1e–g and Supplementary Information 3). This evidence concerns the gene CD9 and non-small cell lung carcinoma.